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Abstract
Hematopoietic stem cells (HSC) derived from cord blood (CB), bone marrow (BM), or mobilized peripheral blood (PBSC) can
differentiate into multiple lineages such as lymphoid, myeloid, erythroid cells and platelets. The local microenvironment is
critical to the differentiation of HSCs and to the preservation of their phenotype in vivo. This microenvironment comprises a
physical support supplied by the organ matrix as well as tissue specific cytokines, chemokines and growth factors. We
investigated the effects of acellular bovine bone marrow extracts (BME) on HSC in vitro and in vivo. We observed a
significant increase in the number of myeloid and erythroid colonies in CB mononuclear cells (MNC) or CB CD34+ cells
cultured in methylcellulose media supplemented with BME. Similarly, in xeno-transplantation experiments, pretreatment
with BME during ex-vivo culture of HSCs induced a significant increase in HSC engraftment in vivo. Indeed, we observed
both an increase in the number of differentiated myeloid, lymphoid and erythroid cells and an acceleration of engraftment.
These results were obtained using CB MNCs, BM MNCs or CD34
+ cells, transplanted in immuno-compromised mice (NOD/
SCID or NSG). These findings establish the basis for exploring the use of BME in the expansion of CB HSC prior to HSC
Transplantation. This study stresses the importance of the mechanical structure and soluble mediators present in the
surrounding niche for the proper activity and differentiation of stem cells.
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Introduction
Hematopoietic stem cell transplantation (HSCT) is an estab-
lished treatment for patients with various hematological malig-
nancies, with an increasing frequency of procedures worldwide
[1]. The source of hematopoietic stem cells (HSC) used for HSCT
includes bone marrow (BM), cord blood (CB), or mobilized
peripheral blood (PBSC).
In the allogeneic HSCT setting, CB represents an ideal cell
source as it is readily available in large numbers and is associated
with a lower risk of graft-versus-host disease (GvHD) [2]. The
major drawback for the use of CB is the relatively limited number
of HSC limiting its use to pediatric patients less than 40 kg of
bodyweight when using a single cord unit [3]. To overcome this
limitation, pooling of double cord is an alternative in adult patients
[4]. This approach, however, has several limitations including
difficulty in finding compatible CB units. As a result, ex-vivo
expansion of the pool of HSCs from a single CB unit represents
the ideal approach to expand applicability of CB for HSCT. It is
important to note that the use of double CB units leads to a similar
rate of GvHD compared to grafts from healthy donors [5].
In the autologous HSCT setting, the major source for HSC is
mobilized PBSC that are collected by aphaeresis and cryopre-
served [6]. These cells contain not only stem cells but also more
mature committed progenitors and precursors that participate to
early engraftment. Ex-vivo expansion of the pool of committed
progenitors and precursors prior to the administration of PBSC
could result in faster engraftment, hence reducing length of
hospital stay and potentially result in cost savings.
The in vivo local microenvironment is critical to support the
differentiation of stem cells or to sustain the phenotype of the stem
cell-derived in vitro differentiated cells [7,8]. This local microen-
vironment comprises a physical support supplied by the organ
matrix as well as tissue specific factors. In previous studies [9], we
demonstrated that acellular organ extracts induce tissue specific
differentiation of BM derived mesenchymal stem cells (MSC). We
first showed that acellular bovine or equine bone extracts induce
osteoblatic differentiation of human bone marrow derived MSC.
We also demonstrated that acellular cartilage extracts (derived
from meniscus and joint cartilage) induce chondrocytic differen-
tiation of BM derived MSC (unpublished data).
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40140In this study, we investigated the effects of acellular bovine
BME on hematopoietic progenitor development in methylcellu-
lose assays and in HSC engraftment in xeno-transplantation
models. We show that BME induce and stimulate the growth of
myeloid and erythroid colonies in methylcellulose cultures of CB
or BM mononuclear cells or CD34 positive cells. Importantly,
we also demonstrate that ex-vivo pretreatment of HSC with
BME significantly improve and accelerate their in vivo engraft-
ment in xeno-transplantation models in NOD/SCID and NSG
mice. These results support the use of BME in the expansion of
CB and PBSC hematopoietic progenitors and/or HSC prior to
HSCT.
Materials and Methods
Ethics Statement
Consent forms detailing the use of human cord blood (CB) and
bone marrow (BM) in our experimental protocol were approved
by the American University of Beirut Medical Center (AUB-MC)
Institutional Review Board (IRB). All animal experiments were
approved by the AUB Institutional Animal Care and Use
Committee (IACUC). Animals were handled under pathogen-
free sterile conditions, maintained under micro-isolators, and fed
sterile food. Finally, this study was performed in accordance with
the principles of the declaration of Helsinki.
Human Cord Blood and Bone Marrow Cells
Samples of CB were obtained from discarded placental and
umbilical tissues, after informed consent from delivering mothers
attending the AUB-MC. BM cells were collected after informed
consent of patients attending the hospital for BM aspirations. Bone
marrow samples were derived from patients diagnosed with
Hodgkin disease or Non-Hodgkin Lymphomas, who had routine
BM assessment as staging for their disease and who were found to
have a normal bone marrow. CB and BM were collected in tubes
containing EDTA, sodium citrate or heparin, and were processed
within 24 hours.
Purification of MNCs by Ficoll
Fresh samples of CB were diluted 1:3 in Iscove’s modified
Dulbecco’s medium (IMDM, GIBCO-BRL, Life Technologies,
Saint Aubin, France) containing 10% fetal bovine serum (FBS,
Life Technologies). Samples were enriched for mononuclear cells
(MNC) by centrifugation on Ficoll/Hypaque (GE Healthcare Life
Sciences, Uppsala, Sweden). This step of density gradient
centrifugation would allow the purification of MNCs from red
blood cells and neutrophils. These cells were either used
immediately for the experiments described below or cryopreserved
in 10% dimethylsulfoxide (DMSO, Sigma GmbH, Roedermark,
Germany) in FBS. Later, cryopreserved cells were thawed at 37uC,
washed in phosphate-buffered saline (PBS), and resuspended in
medium for the specific experiment. After thawing, cell viability
was monitored by Trypan blue dye exclusion.
Isolation of CD34
+ Cell Populations
Enrichment of HSCs was obtained by isolation of the CD34
+
fraction from BM cells collected from free of disease patients
after informed consent. MS columns and mMACS magnetic
beads (Miltenyi Biotec, Surrey, UK) or EasySep columns (Stem
Cell Technologies, Vancouver, Canada) were used for this
purpose. Using a magnetic separation procedure, the CD34
+
fraction of HSCs was positively selected by labeling with a
CD34 antibody that is anchored to magnetic beads. As a result,
about one million CD34 positively selected cells were isolated
from 100 million BM MNCs. Purity of the isolated fraction was
measured by flow cytometry and was always determined to be
greater than 90%. Data acquisition and analysis was performed
with CellQuest or Diva softwares from Becton Dickinson (BD,
New Jersey, USA) or with FlowJo software (Treestar, Oregon,
USA).
Bovine Bone Marrow Extracts (BME)
Extracts are sterile acellular lyophilizates from bovine BM
matrix and were supplied by Ossacur AG, (Oberstenfeld,
Germany). This new technology is based on the extraction of
extracellular matrix proteins from animal tissue and contains a
mixture of all growth factors and cytokines within the matrix.
Briefly, extracts were prepared, aseptically, from bone marrow of
disease-free, young (,12 months old) calves of closed herds. Bone
marrows were pulverized and delipidated with acetone for 60 min
at 4uC. The resulting particles were demineralized in 0.6 N
hydrochloric acid for 60 min at 4uC. Particles were then washed in
deionized water, extracted with 4 M guanidine hydrochloride and
ultrafiltered using 3 K nominal molecular cut-off membranes.
Extracts were then reconstituted in water from the initial stock
solution in order to have a final concentration of 0.0138 mg/ml.
This concentration was selected based on previous liquid culture
experiments, which showed optimum differentiation results (data
not shown).
Culturing and Treatment of MNCs and CD34
+ Cells
MNCs were cultured, in 25 cm
2 Falcon dishes, in Iscove’s
modified Dublecco’s medium (IMDM, GIBCO-BRL, Life Tech-
nologies,) supplemented with 10% fetal bovine serum (FBS) for 7
days. On the other hand, about 20,000 CD34
+ cells were seeded in
6-well plates and suspended at 10
5 cells/mL in serum-free
StemSpan H3000 culture medium (Stem Cell Technologies).
The CD34+ cells were supplemented with SCF (25 ng/mL) and
G-CSF (10 ng/mL) recombinant human factors for 13 days
(Invitrogen, Life Technologies). Cells were treated with BME,
diluted with culture medium to have a final concentration of
0.0138 mg/ml. Control cells were left un-treated, i.e. without the
addition of BME. Cell suspensions were incubated at 37uCi na
5%CO2/95% air atmosphere, after which they were collected,
washed in IMDM, counted by Trypan blue exclusion, analyzed
for progenitor and stem cells, and engrafted into NOD-SCID or
NSG mice.
Colony Forming Cell (CFC) Assay
CD34
+ cells from each CB sample were suspended in IMDM/
10% FBS and plated on methylcellulose-based media (HSC002,
HSC003, and HSC004, R & D systems, Lille, France), with or
without the addition of BME. The human methylcellulose base
media HSC002 contains 1.3% methylcellulose, 25% FBS, 2%
BSA, 2 mM L-glutamine, and 5610
25 M beta-mercaptoethanol.
The human methylcellulose complete media HSC003 contains the
basic HSC002 media and is supplemented by rh-SCF (50 ng/mL),
rh-GM-CSF (10 ng/mL), rh-IL-3 (10 ng/mL), and rh-Epo (3 U/
mL). The human methylcellulose complete media HSC004 is
similar to HSC003 media but without Epo. Cells were plated, in
duplicate, at a final concentration of 100 cells/9.6 cm
2 dish.
Colonies consisting of CFU-GM (Granulocyte Macrophage),
CFU-E/BFU-E (Erythroid), and CFU-GEMM (Granulocyte
Erythroid Macrophage Megakaryocyte) were counted at days
14–16 under an inverted microscope.
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NOD/SCID (NOD.CB17-Prkdc
scid/J) and NSG mice
(NOD.Cg-Prkdc
scid Il2rg
tm1Wjl/SzJ) were obtained from the Jackson
Laboratory (Maine, USA).
Conditioning Regimen
We used the alkylating agent, busulfan (Busilvex, Pierre Fabre,
Boulogne, France), as conditioning regimen for transplantation.
Busulfan is a cell cycle non-specific drug that functions similarly to
total body irradiation (TBI). It provides equivalent sensitivity to
the standard irradiation regimen conditioning protocol in
immune-compromised mice, as demonstrated by HSC detection,
evaluated by limiting dilution analysis of SRC [10]. Mice aged 6–
10 weeks received intra-peritoneal (ip) injection of Busulfan at a
dose of 22 mg/kg, for 3 consecutive days before transplantation.
HSCs are then injected intravenously.
Transplantation of Isolated Cells into NOD/SCID or NSG
Mice
Purified cell populations (MNCs or CD34
+), at the indicated
dose, were transplanted by tail-vein intravenous (iv) injection into
Busilvex treated mice according to standard protocols. Briefly,
human cells were suspended in 250 ml IMDM tissue culture
medium (Sigma) containing 1% human serum albumin (HSA,
ZLB Behring GmbH, Marburg, Germany). Groups of five mice
each, received a dose of viable human CB MNCs (1.5610
6,
3610
6,o r4 610
6 cells/mouse). If purified CD34
+ cells were used,
mice were transplanted with 50610
3 cells/mouse. The effect of
BME on engraftment was studied by culturing the same amount of
cells with or without BME for 7 days.
Mice Sacrifice and Collection of Samples
Mice were sacrificed at 3 or 6 weeks after transplantation. Mice
were euthanized by Isoflurane inhalation (Abbot Laboratories,
Kent, UK) then cervical dislocation. BM was collected from the
long bones of the two posterior limbs (femurs, tibiae, and iliac
crests) by flushing with IMDM containing 10% FBS. Single cell
suspensions were prepared by drawing the BM cells through a 27-
gauge needle, then expelling them back through the needle and
through a nylon mesh (70 m strainers, BD).
Flow Cytometry and Assessment of Engraftment
Collected BM samples from NOD/SCID or NSG mice were
stained with various human specific monoclonal antibodies and
analyzed by flow cytometry, after 3 or 6 weeks of transplantation.
Briefly,approximately10
5cellsweresuspendedin50 mlofPBS/5%
FCS/5% human serum for 30 min at 4uC, in order to block Fc
receptors. Cells were then washed in PBS containing 10%FBS, and
incubated with monoclonal antibodies at a concentration of 5 mg/
mlfor30 minat4uC.CellswerestainedwithhumanspecificFITC-
conjugated anti-CD33, PE-conjugated anti-CD19 and Phycoery-
thrin-Cyanin 5 (PE-Cy5/PC5)-conjugated anti-CD45. Cells were
also stained with human specific FITC-conjugated anti-CD235a
(Glycophorin A), PE-conjugated anti-CD36 and Peridinin-Chloro-
phyll-Protein complex (PerCP)-conjugated anti-CD45 antibodies.
Followingstaining,cellswerewashedinPBS/5%FBSandanalyzed
on a flow cytometer (BD FACSCalibur or BD FACSCanto, New
Jersey, USA). Gates were set up to exclude nonviable cells and
debris. For eachmouse analyzed, an aliquot of cells was also stained
with isotype control mouse immunoglobulin G (IgG) conjugated to
FITC, PE, PC5 or PerCP (mouse IgG1, IgG2a, IgG2b, or IgM;
Becton-Dickinson). BM cells from an untransplanted mouse were
stained in parallel as a negative control. Fluorescence levels
excluding greater than 99% of the cells in these negative controls
were considered to be positive and specific for human staining.
About 50,000 events were collected for data analysis. Data
acquisition was done using SciQuest or Diva softwares from Becton
Dickinson while data analysis was performed on flowJo (Treestar,
USA). The level of engraftment (i.e. % of human cells) in the BM of
NOD/SCID or NSG mice was then measured by adding the
engraftment levels from the human leukocytes population (CD45
+
cells) in addition to immature erythroblasts
(CD45
2CD36
+CD235a
+). Furthermore, multi-lineage differentia-
tion of human cells in murine BM was also determined. Indeed,
human CD45
+ cells were further gated based on characteristic
forward and side scatter properties into lymphoid and myeloid
populations.Multi-lineageengraftmentisdefinedbythepresenceof
separate CD45
+CD33
+ (myeloid) and CD45
+CD19
+ (lymphoid)
populations with appropriate scatter characteristics. Moreover,
erythroid populations made up of immature erythroblasts
(CD45
2CD36
+CD235a
+) or mature RBC’s
(CD45
2CD36
2CD35a
+) were also determined as explained in
previous publications [10,11]. Finally, in order to confirm human
engraftment,murineBMcellswerealsostainedwithmurinespecific
FITC-conjugated anti-CD45. The engraftment pattern of mice
transplanted with purified CD34
+ cells was similar to what is
observed after transplantation of unsorted CB cells. CD45 and
CD34 antibodies were purchased from Becton Dickinson (NJ,
USA). Allotherantibodies werefrom Beckman Coulter(California,
USA). It’s important to note that myeloid and B lymphoid
reconstitution can be easily attained in NOD-SCID and NSG mice
by the transplantation of human HSCs. Several reports have
suggestedthatTcellsmaybeabletodevelopinthethymusofNOD-
SCID mice transplanted with human CD34 cells. In particular, van
derLooetal.succeededinrepopulatingamousethymuswithhuman
cellsbyadministeringG-CSFandstemcellfactor.However,mostof
the T cells were double positive (DP) cells, and a functional analysis
of these T cells has not been completed [12]. Recently, Yahata et al
reportedanewmodelforthestudyofT-LymphocytesintheNOD/
Shi-scid, IL2-Receptor gamma null mouse background [13].
Statistical Analysis
Results are expressed as individual data or as the mean6SD.
Statistical comparisons were performed using the Student’s t-test
in order to determine statistical significance. Paired t-test was used
for methylcellulose experiments. The p value was determined and
values for p,0.05 or p,0.001 were considered significant. The
Microsoft Excel and SPSS Packages were used to perform
statistical analysis.
Results
Bone Marrow Extracts Enhance Hematopoietic Colony
Formation
We first investigated the effect of acellular BME on the
proliferation and differentiation of CB hematopoietic progenitors
using colony-forming assays in methylcellulose. A total of 20,000
CB MNCs from each patient (n=6) were plated on different types
of methylcellulose-based media (HSC002, HSC003, and
HSC004), in the presence or absence of BME (CB+BME or CB,
respectively). In HSC002 media, which does not contain any
added growth factors, the addition of BME increased the number
of CFU-G/M colonies by 1.7-fold (Figure 1A, upper panel). In
HSC003 media, which contains SCF, GM-CSF, IL3 and Epo, the
addition of BME resulted in a significant increase of approximately
1.5 fold in the number of myeloid colonies (CFU-G/M), erythroid
colonies (BFU-E) and mixed colonies (CFU-GEMM) (p,0.05 for
Effect of Bone Marrow Extracts on Transplantation
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which contains SCF, GM-CSF and IL3, BME increased the
number of myeloid colonies by at least 2-fold (Figure 1A, lower
panel). Similar results were obtained when positively selected CB
CD34
+ cells were used. Indeed, when 100 CD34
+ cells from each
CB sample (n=4), were plated on the basic methylcellulose media
without any added factors (HSC002), myeloid colonies (CFU-G/
M) appeared only in the presence of BME (Figure 1B, upper
panel). Moreover, addition of BME resulted in a significant
increase of myeloid colonies (2 fold) in HSC003 and HSC004
(p,0.001), of erythroid colonies in HSC003 (p,0.001), and of
GEMM in HSC003 (p,0.05) (Figure 1B, middle and lower
panels). Since HSC002 and HSC004 media presented neither
CFU-GEMM nor BFU-E (erythroid) colonies, we may speculate
that BME do not contain any EPO activity. Overall, BME
increased the number of myeloid and erythroid colonies in
methylcellulose culture from both CB MNC and CB CD34
+ cells.
Bone Marrow Extracts Enhance Human Cord Blood
Derived Mononuclear Cell Engraftment in Immune-
deficient Mice
The current models for assessment of transplantable human
HSCs are based on the use of immune-deficient mice such as
NOD/SCID [14] (NOD.CB17-Prkdc
scid/J) and NSG [15]
(NOD.Cg-Prkdc
scid Il2rg
tm1Wjl/SzJ) mice strains. NOD/SCID
mice are characterized by low NK cell activity [16], in addition
to B-cell, T-cell, and complement defects. NSG mice represent a
more permissive xeno-transplantation model generated from
NOD/SCID and the IL-2 receptor gamma c (CD132) knock-out
mice and characterized by complete lack of NK activity.
A representative example of the data in an NSG mouse is shown
in Figure 2. At six weeks, the percentage of engraftment (CD45
+
fraction) increased from 5% in an NSG mouse injected with
untreated CB MNC cells to about 24% in a mouse injected with
cells treated with BME. This increase in engraftment was mainly
due to an increase in the number of myeloid cells (CD33
+,R 4
region), which represented more than 90% of engrafted cells.
Finally, the percentage of engraftment due to immature erythro-
blasts increased from around 1.11% in the mouse injected with
untreated CB MNC cells to around 2.92% in the mouse injected
with CB MNC treated with BME (Figure 2).
Two groups of NOD/SCID mice (n=5 each) received CB
MNCs that were put in culture for 7 days, in the presence or
absence of BME. A third group (n=5) served as a negative control
and was injected a saline solution. Mice were sacrificed six weeks
after transplantation. The percentage of engraftment, as deter-
mined by the human pan leucocytic CD45 marker, significantly
increased from 3% in the mice that have received untreated CB
MNC cells to more than 10% in the mice which received CB
MNC cells cultured in the presence of BME (p,0.05) (Figure 3,
upper panel). When subpopulations were examined, the increase
in engraftment was significant for the myeloid populations
(p,0.05) but not for lymphoid cells (Figure 3, lower panel).
Similar results were obtained in NSG mice (n=4 for each group)
which received CB MNCs that were put in culture for 7 days, in
the presence or absence of BME. The percentage of engraftment,
at 6 weeks of transplantation, significantly increased from 5% in
the mice that have received cells cultured without BME to 20% in
the mice that received cells cultured with BME (p,0.05) (Figure 4,
upper panel). When subpopulations were examined, the increase
in engraftment was significant for both myeloid (p,0.05) and
lymphoid (p,0.05) populations (Figure 4, lower panel).
In order to assess erythroid engraftment, the percentage of
engraftment was measured at three weeks instead of six weeks.
The time point at 3 weeks allows seeing engraftment due to
immature erythroblasts and RBC’s. NSG mice (n=3 for each
group) received CB MNCs that were put in culture for 7 days, in
the presence or absence of BME. In these conditions, the
percentage of engraftment significantly increased from 12% in
the mice that have received cells cultured without BME to 27% in
the mice that received cells cultured with BME (p,0.05) (Figure 5,
upper panel). When subpopulations were examined, the increase
in engraftment was only significant for immature erythroblasts
(CD45
2CD36
+,p ,0.05) (Figure 5, lower panel).
Bone Marrow Extracts Enhance Human Bone Marrow
Derived CD34 Positive Cells Engraftment in Immune-
deficient Mice
We then investigated the effect of BME on positively selected
CD34 cells derived from normal human bone marrow, using the
immune-deficient NSG mice model. Two groups of NSG mice
(n=5 each) received 50610
3 CD34 positive cells that were put in
culture for 13 days in the presence or absence of BME. A third
group (n=5) served as a negative control and was injected a saline
solution. Mice were sacrificed six weeks after transplantation. The
percentage of engraftment, as determined by the human pan
leucocyte CD45 marker, significantly increased from 8% in the
mice that have received untreated CD34 positive cells to more
than 31% in the mice that received CD34 positive cells cultured in
the presence of BME (p,0.05) (Figure 6, upper panel). When
subpopulations were examined, the increase in engraftment was
significant for both myeloid (p,0.05) and immature erythroblasts
(p,0.05) populations but not for lymphoid cells (Figure 6, lower
panel).
Discussion
Traditionally allogeneic HSCT was offered only to patients with
available HLA-matched sibling donors. Introduction of unrelated
donors whether using unmanipulated BM, mobilized PBSC or CB
has certainly expanded applicability of allogeneic HSCT to
patients with various hematologic diseases. Use of umbilical CB
cells offers several advantages such as immediate availability, lack
of risks to donors, and a lower incidence of GVHD despite the
presence of significant HLA disparity. Expanding applicability of
allogeneic HSCT using CB cells, particularly to adult patients, has
been faced with several challenges including a limited number of
available progenitor HSCs in a single CB unit and a delayed
hematopoietic cell engraftment. For instance, adult patients
undergoing CB allogeneic HSCT have a high likelihood of non-
relapse mortality during the early post transplantation phase
mainly due to poor recovery of blood counts as a result of the
lower number of progenitor HSC compared to BM or PBSC [17].
Transplantation of two partially HLA-matched umbilical CB units
is feasible and facilitates performing the procedure in adult
patients [18]. However, identification of two compatible CB units
is not always possible. Accordingly, ex vivo expansion methods to
increase cell dose of single CB units represents an unmet need to
continue to offer potentially curative allogeneic HSCT to
otherwise deadly hematologic and non-hematologic diseases.
Increasing evidence supports a vital role of the local microen-
vironment in vivo in the differentiation of stem cells and for the
maintenance of the phenotype of differentiated cells. This local
microenvironment comprises a physical support supplied by the
organ matrix/marrow as well as tissue specific factors such as
cytokines, chemokines and growth factors. It is now clear that
ECM-based control of the cell may also occur through multiple
physical mechanisms, such as ECM geometry, ECM elasticity, or
Effect of Bone Marrow Extracts on Transplantation
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addition to the interactions of ECM ligands with cell surface
receptors [20]. We have previously demonstrated [9] that acellular
organ ‘‘extracts’’ induce tissue specific differentiation of bone
marrow derived mesenchymal stem cells (MSC). Indeed we
showed that acellular bovine or equine bone extracts induce
osteoblatic differentiation of human BM derived MSC. In
addition, cartilage (meniscus and joint) extracts specifically caused
the differentiation of MSCs into chondrocytes, with no cross-
reactivity to bone. Differentiation markers of either bone- or
cartilage- induced differentiation of MSCs were selective and
tissue-specific. In this study we postulated that extracts originating
from BM should contain factors involved in differentiation and
maintenance of HSCs.
We investigated the effects of acellular bovine BME on
hematopoietic progenitor development in vitro, using methylcellu-
Figure 1. Bone marrow extracts enhance hematopoietic colony formation. A) About 20,000 CB MNCs from each patient were plated on
methylcellulose-based media (HSC002, HSC003, and HSC004), in the presence or absence of BME (CB+BME or CB, respectively). Methylcellulose media
contained no growth factors (HSC002), SCF+GM-CSF+IL3+Epo (HSC003), or SCF+GM-CSF+IL3 without Epo (HSC004). Colony forming units (CFU)
consisting of CFU-G/M (Granulocyte or Macrophage or both), CFU-E/BFU-E (Erythroid), and CFU-GEMM (Granulocyte Erythroid Macrophage
Megakaryocyte) were counted at day 16 using an inverted microscope. Data represents an average of 6 different samples. B) A total of 100 CB CD34+
cells from each patient were plated on methylcellulose media (HSC002, HSC003, and HSC004), in the presence or absence of BME (CB+BME or CB,
respectively) as described above. Data represents an average of 4 samples used in the study. Paired TTest was used for statistical significance
(*: p,0.05, **: p,0.001).
doi:10.1371/journal.pone.0040140.g001
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treated cells in vivo, using immune-deficient mice models. We show
that the local microenvironment stimulates the growth of myeloid
and erythroid colonies in methylcellulose cultures and is critical for
in vivo engraftment of HSC in xeno-transplantation models.
Indeed, the following several lines of evidence support the above
Figure 2. Multilineage engraftment of human CB MNC in NSG mice. In this study, NOD/SCID or NSG mice received iv busulfan conditioning
followed by iv injection of CB MNC or CD34
+ cells that were previously cultured in vitro for 7 days, in the presence or absence of BME. This figure
represents NSG mice which received iv injection of 3610
6 CB MNC according to the same protocol. Mice were sacrificed and bone marrow cells were
harvested from femurs, tibia and pelvis and examined for multilineage engraftment by flow cytometry according to the following gating strategy: A)
Live cells were first gated using forward scatter versus side scatter plots (R1 region). The three plots represent mice injected with saline (negative
control), CB, or CB+BME; respectively. B) Human leucocytes were then gated using human CD45 staining (pan-leukocyte marker, R2 region). C) From
CD45
+ gate (R2 region), cells were then examined for multi-lineage engraftment defined by the presence of separate lymphoid (CD45
+CD19
+,R 3
region) and myeloid (CD45
+CD33
+, R4 region) populations. D) The population of CD45
2 cells were gated in order to determine the erythroid
populations. Indeed, erythroid populations made up of mature RBCs (CD45
2CD36
2CD235a
+, R5 region) or immature erythroblasts
(CD45
2CD36
+CD235a
+, R6 region) were also determined. It’s important to note that the CD36
+CD235a
2 population, which is not present in the
controls, does not represent immature erythroblasts but are CD45+ mature cells. The percent engraftment was defined as the total number of
leucocytes and immature erythroblasts (CD45
+ and CD45
2CD36
+CD235a
+ cells).
doi:10.1371/journal.pone.0040140.g002
Figure 3. Bone marrow extracts enhance human cord blood
derived mononuclear cell engraftment in NOD/SCID mice. Two
groups of NOD/SCID mice (n=5 each) received 3610
6 CB MNCs
previously cultured for 7 days, in the presence or absence of BME. A
third group (n=5) served as a negative control and were injected with
saline. Mice were sacrificed six weeks after transplantation. A) The
percentage of engraftment was determined using the human pan
leukocyte CD45 marker. B) The contribution of myeloid and lymphoid
populations to total human leukocyte engraftment was determined
using CD33, CD19 and CD45 markers, respectively. *: p,0.05.
doi:10.1371/journal.pone.0040140.g003
Figure 4. Bone marrow extracts enhance human cord blood
derived mononuclear cell engraftment in NSG mice. Two groups
of NSG mice (n=4 each) received 1.5610
6 CB MNCs previously cultured
for 7 days, in the presence or absence of BME. A third group (n=5)
served as a negative control and was injected with saline. Mice were
sacrificed six weeks after transplantation. A) The percentage of
engraftment was determined using the human pan leukocyte CD45
marker. B) The contribution of myeloid and lymphoid populations to
total human leukocyte engraftment was determined using CD33, CD19
and CD45 markers, respectively. *: p,0.05.
doi:10.1371/journal.pone.0040140.g004
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in the number of myeloid and erythroid colonies in CB MNCs
cultured in methylcellulose media supplemented with BME, when
compared to cells cultured without BME. (2) A similar increase of
about 2-fold in the number of CFU-G/M, CFU-GEMM and
BFU-E was also observed when CB CD34
+ cells were used. (3)
Pretreatment with BME during ex-vivo culturing of HSCs induces
an increase in the level of engraftment in vivo in xeno-
transplantation mice models (NOD/SCID and NSG). (4) This
increase in engraftment levels is supported by an increase in the
number of differentiated cells. (5) The effect of BME on multi-
lineage engraftment and HSC transplantation in vivo was
confirmed using CB MNCs, BM MNCs and especially CD34
+
cells, using both mice models. (6) MNCs and CD34+ cells were
cultured for only 1 week or 13d, respectively, instead of the 2–3
weeks used by others. This new method, using BME, with reduced
period of culturing time leads to a maximum yield of progenitor,
precursor and differentiated cells. (7) Finally, it’s important to note
that engraftment in the different conditions tested was due not
only to myeloid cells, but also to immature erythroblasts.
In an attempt to elucidate whether the differentiation of stem
cells in vitro using BME is due to endogenous differentiation factors,
different factors were analyzed by Bioscientia GmbH (Ingelheim,
Germany). The following results were obtained: Epo (11.3 mIU/
mL), IL-2 (2.2 pg/mL), IL-3 (1.3 pg/mL), IL-6 (,1.0 pg/mL),
and IL-10 (1.9 pg/mL). Epo concentrations were well below the
20
th percentile, which reflects insufficient levels to explain the
observed erythropoiesis. Since Epo levels in HSC0003 is in vast
excess to that present in our extract, therefore the data suggests
that other unknown factors (such as ECM, growth factors, etc…)
should be implicated in differentiation.
Figure 5. Bone marrow extracts enhance human erythroid
engraftment in NSG mice. Two groups of NSG mice (n=3 each)
received 4610
6 CB MNCs previously cultured for 7 days, in the presence
or absence of BME. A third group (n=5) served as a negative control
and was injected with saline. Mice were sacrificed three weeks after
transplantation. A) The percentage of engraftment was determined
using the human pan leukocyte CD45 marker. B) The contribution of
myeloid, lymphoid and erythroid populations to total human leukocyte
engraftment was determined using CD33, CD19, CD36 and CD45
markers, respectively. *: p,0.05.
doi:10.1371/journal.pone.0040140.g005
Figure 6. Bone marrow extracts enhance human bone marrow
derived CD34 positive cells engraftment in immunodeficient
mice. Two groups of NSG mice (n=5 each) received 50610
3 bone
marrow derived CD34 positive cells previously cultured for 13 days, in
the presence or absence of BME. A third group (n=5) served as a
negative control and was injected with saline. Mice were sacrificed six
weeks after transplantation. A) The percentage of engraftment was
determined using the human pan leukocyte CD45 marker. B) The
contribution of myeloid, lymphoid and erythroid populations to total
human leukocyte engraftment was determined using CD33, CD19,
CD36 and CD45 markers, respectively. *: p,0.05.
doi:10.1371/journal.pone.0040140.g006
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and consequently increased rates of infectious complications due
to the relatively low number of progenitor cells in the graft [21].
Therefore, different methods of ex vivo expansion of CB have been
used in order to deliver higher cell doses and improved outcomes
[22]. In fact, a major goal of ex vivo expansion is the production of
optimal number of HSCs for transplantation as well as an enough
number of specific progenitor cells for rapid recovery from
pancytopenia. Different teams have now published promising
reports of CB progenitors expanded in liquid cultures [23,24,25].
These include the use of different cocktails of cytokines (such as
SCF, IL-3, IL-6, G-CSF, TPO, and Flt-3 ligand), marrow-derived
mesenchymal cells [26,27], Notch ligand expansion [28], biore-
actors [29], or different stromal [30] co-culture conditions.
Usually, ex vivo expansion is performed on whole CB units; which
is then infused alongside with an un-manipulated CB
[29,31,32,33]. New expansion methods attempt to develop
serum-free culture systems [34,35], optimize culture conditions
[36,37], use histone deacetylases [38] which promote self-renewal,
use glycogen synthase kinase (GSK)-3 inhibitors [39] which
maintain HSC pluripotency, or use tetraethylenepentamine
(TEPA) [40] which modulates the proliferation and differentiation
of primitive hematopoietic progenitors. Moreover, another new
system currently being used is the DIDECO ‘‘Pluricell System’’
which is a commercially available closed device composed of an
expansion chamber and a kit of certified reagents that allow
haematopoietic stem cell expansion [41]. Recently, de Lima et al
[33] has shown that TEPA (also called StemEx) attenuates the
differentiation of ex vivo cultured HSCs resulting in preferential
expansion of early progenitors. In a recent phase I/II trial on
CD133+ CB HSCs cultured in media containing TEPA, together
with SCF, FLT-3 ligand, IL-6, and TPO, nine out of ten patients
showed engraftment with an increase of CD34+ cell count, better
median time to neutrophil, better platelet engraftment, and no
cases of grades 3–4 acute GvHD. Indeed, it has been shown that
time to neutrophil engraftment is strongly associated with CD34+
cell dose.
By mimicking the niche, BME were added to our cells prior to
their implantation into the mice, which proved to produce an
increase in the number of differentiated progenitors and an
increase in the engraftment levels. As compared to other currently
tested expansion methods, one advantage of our system is that
BME were used without the addition of any cytokines, which
significantly reduces the cost. A further advantage of our system is
that the expansion of cells, after incubation with BME, was not
selective of the short-term (low quality) HSCs at the expense of the
long-term (high quality) reconstituting HSC. This statement is
supported by the engraftment after 6 weeks. However, expansion
of the short-term progenitors is also clinically useful since it helps
in initial recovery (short-term hematopoietic reconstitution) and
especially when combined with un-manipulated CB. However, in
order to clearly confirm self-renewal and long term reconstitution
from HSCs (LT-SRC), further studies need to be performed using
secondary transplantation or engraftment at 12–18 weeks. A third
advantage of our system is that cells were cultured for only 1 week
for MNCs (or approx. 13 days in the case of CD34+ cells) instead
of the 2–3 weeks period used by others [23,26,33], which
minimizes the risks associated with long term tissue culture such
as genetic instability or bacterial and fungal contamination.
These results establish the basis for exploring the use of BME in
the expansion of CB progenitors and/or HSC prior to HSCT. It is
conceivable that a mixture of an ex-vivo expanded/differentiated
pool with an untreated pool will result in improved short term and
long term reconstitution. This study stresses the importance of the
mechanical structure and soluble mediators present in the
surrounding niche for the proper activity and differentiation of
stem cells.
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